In 2021 U.S. Food and Drug Administration (FDA) approved both 68Ga-PSMA-11 and 18F-DCFPyL administration in patients with suspected prostate cancer metastases who are potentially curable by surgery or radiation therapy and patients with suspected prostate cancer recurrence [20,21]. This evidence concerns the gene FOLH1 and Familial prostate cancer.